About this Journal Submit a Manuscript Table of Contents
Neurology Research International
Volume 2012 (2012), Article ID 454957, 13 pages
http://dx.doi.org/10.1155/2012/454957
Review Article

The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas

1First Department of Pathology, Laiko Hospital, National and Kapodistrian University of Athens Medical School, 11527 Athens, Greece
2Department of Biological Chemistry, National and Kapodistrian University of Athens Medical School, 11527 Athens, Greece

Received 30 July 2011; Revised 5 December 2011; Accepted 9 December 2011

Academic Editor: Stuart Burri

Copyright © 2012 Elias A. El Habr et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Astrocytomas, the most common type of gliomas, and especially grade IV glioblastomas are “endowed” with strong proliferation and invasion potentials, high recurrence rate, and poor patients' prognosis. Aberrant signaling of AKT-mTOR (mammalian target of rapamycin) has been implicated in carcinogenesis. This paper is focused on the impact of deregulated AKT-mTOR signaling components in the clinical outcome and prognosis of human astrocytomas. Current therapeutic targeting of astrocytomas with AKT-mTOR inhibitors in preclinical and clinical stage is also discussed, including future perspectives regarding the management of these devastating tumors.